Atara, Memorial Sloan Kettering expand CAR-T deal

Atara Biotherapeutics Inc. (NASDAQ:ATRA) and Memorial Sloan Kettering Cancer Center (New York, N.Y.) expanded a 2014 deal in order to give Atara access to several MSKCC technologies including a CAR T construct and methods for designing CAR T immunotherapies. Atara said it will pay MSK development and regulatory milestones and tiered single-digit royalties. MSKCC did not respond to inquiries...